SRTS Stock Summary and Trading Ideas (Sensus Healthcare | NASDAQ:SRTS)

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.

Sensus Healthcare trades on the NASDAQ stock market under the symbol SRTS.

As of January 28, 2026, SRTS stock price climbed to $5.11 with 102,025 million shares trading.

SRTS has a beta of 0.08, meaning it tends to be less sensitive to market movements. SRTS has a correlation of 0.00 to the broad based SPY ETF.

SRTS has a market cap of $83.93 million. This is considered a Micro Cap stock.

Last quarter Sensus Healthcare reported $7 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.05.

In the last 3 years, SRTS traded as high as $9.33 and as low as $1.79.

The top ETF exchange traded funds that SRTS belongs to (by Net Assets): VTI, VXF, DFSV, DFAS, IWC.

SRTS has underperformed the market in the last year with a price return of -24.7% while the SPY ETF gained +17.2%. However, in the short term, SRTS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +56.7% vs +1.8% return in SPY. But in the last 2 weeks, SRTS shares have been beat by the market, returning -3.6% compared to an SPY return of +0.2%.

SRTS support price is $4.78 and resistance is $5.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRTS shares will trade within this expected range on the day.